“Since the time we moved to the IZB, our headcount grew steadily from 6 to 60 employees. The IZB supported us continuously and we look forward to being part of the IZB in future.”

Michael Scholl, CEO & Dr. Andreas Seidl, COO
LEUKOCARE AG

“From the IZB into the world – serving scientists in more than 50 countries.”

Dr. Marion Jung, CHROMOTEK GMBH

“The IZB is a blessing in the greater Munich area for founders who initially need small spaces and laboratory environments to start their businesses.”

Heimo Adamski, Managing Director 4GENE GmbH

“Pets make a difference in our life; we should make a difference in theirs. Therefore, we are glad for the opportunity to be the first company at IZB with a veterinary ocus.”

Dr. Kathrin Ladetzki-Baehs, Managing Director adivo GmbH

“We have found a great opportunity to expand effectively from basic research to application at the top location in IZB. For many years now, we have been an integral part of the campus and we enjoy the interaction with the other companies.”

Ulrich Scherbel, CEO AMSilk GmbH

“As we are supporting innovative companies, the IZB is an ideal location for us, because of its reputation and networking opportunities.”

Dr. Stefan Ullrich, Managing Partner ARS³ Pharma Management GmbH & Co. KG

“We look forward to you expanding the leading biotech cluster in Europe and its strong network of unique companies, doubling the area by 2025 and quadrupling it by 2030.”

Dr. Kai Lamottke, Managing Director Bicoll GmbH

“Before founding Bind-X, we evaluated 5 biotech clusters in 4 European countries. The decision in favor of the IZB was the right one and clearly contributed to our success.”

Martin Spitznagel, CEO & Founder Bind-X GmbH

“We aim to discover and develop the next generation of small molecule immunomodulatory compounds to improve the standard of care. The expertise of our colleagues in Martinsried is a key element to achieve this.”

Dr. Sierk Poetting, CFO & COO BioNTech SE

“IZB offers an ideal working environment for us. Proximity of other start-ups, university and Max Planck Institutes is stimulating and the thought exchange with colleagues from other firms is always possible.”

Dr. Manfred Rüdiger, Managing Director CatalYm GmbH

“The fact that IZB is a hub of cutting-edge technologies, centrally placed between University and Max Planck Institute, is a great asset for Crelux.”

Dr. Gundel Hager, Managing Director Crelux GmbH, a WuXi AppTec company

“The IZB also supports small drug research companies, for which we are very grateful.”

Dr. Franz Kerek, CEO DoNatur

The start-ups at the IZB

The Innovation and Start-up Centers Biotechnology (IZB) in Martinsried and Weihenstephan offer start-ups a creative environment in cutting-edge research at Martinsried Campus and Weihenstephan Campus. Entrepreneurs benefit from high-quality building infrastructure, flexibly designed office space and furnished laboratory units (S1 laboratories) at fair prices.

Successful companies that have emerged from the IZB include Medigene AG, Morphosys AG, Micromet GmbH (today Amgen Inc.), Octopharma GmbH, Corimmun GmbH (today Janssen-Cilag), Proteros GmbH, Coriolis Pharma Research GmbH, Rigontec GmbH (today MSD) and Exosome Diagnostics (today Bio-Techne) as well as the 4SC AG.

The start-ups at the IZB

Start-ups currently based

Former start-ups

IZB on YouTube

IZB on linkedIn